Utilizziamo i cookie per offrire supporto in live chat e per mostrare contenuti che riteniamo possano interessarti. Se accetti l’utilizzo dei cookie da parte di markets.com, fai clic su accetto.
I CFD sono strumenti complessi e presentano un alto rischio di perdere soldi rapidamente a causa della leva finanziaria. Il 76,3% dei conti di clienti al dettaglio perde denaro facendo trading con i CFD con questo fornitore. Devi verificare se comprendi pienamente come funzionano i CFD e se puoi permetterti di correre il rischio elevato di perdere i tuoi soldi.
Giovedi Dec 14 2023 07:04
4 min
Pfizer shares sink on lower COVID revenue prospects
Pfizer shares slide as revenue, profit forecasts fall below Wall Street expectations
On Wednesday, pharmaceutical giant Pfizer projected 2024 revenue and profit below Wall Street's expectations, resulting in a 9% decline in the PFE share price, despite an increase in the firm’s cost-cutting target by $500 million.
A decrease in annual COVID vaccination rates and demand for treatments in 2023 has impacted the sales of Pfizer's COVID products, including Paxlovid and the vaccine Comirnaty. These products, which significantly contributed to its revenue in the past two years, are now expected to generate $8 billion in total sales in 2024.
The same concerns have plagued other drugmakers whose shares surged during the pandemic. Moderna shares dropped by 4.1%, and Pfizer's German partner in the vaccine, biotech firm BioNTech SE, saw a 3.9% decline in premarket trading.
Fizer has also faced challenges due to a significant decrease in sales of its COVID-19 vaccine and its antiviral pill Paxlovid, both of which contributed to generating over $100 billion in revenue last year.
Analysts had anticipated sales of Comirnaty alone to exceed $8 billion, in addition to more than $5 billion from Paxlovid. The decline in COVID product sales prompted Pfizer to slash its headcount and expenses, expected to save at least $4 billion annually. In November, the company cut 500 jobs at its Sandwich, Kent site in the UK.
The move appears to have done little to reassure investors, with New York-listed Pfizer shares shedding close to 9% in Wednesday trading. To make up for the shortfall in its pipeline, the U.S. drug manufacturer announced its plans to buy Seagen, an oncology drugmaker, for $43 billion earlier this year.
Scegli i tuoi punti di movimento
Calcola il P/L ipotetico (costi e spese aggregati) se avessi aperto una posizione quest’oggi..
Mercati
ETF
ETF
Criptovalute
Azioni
Valuta
Obbligazioni
Materie Prime
Indice
Strumento
Porsche
Procter & Gamble
Roku Inc
Deere
Quanta Services
Yandex
UniCredit
Rolls-Royce
Inditex
Deliveroo Holdings
Goldman Sachs
Coca-Cola Co (NYSE)
Infosys
Toro
ChargePoint Holdings Inc
Comcast
Chipotle
Campari
The Cheesecake Factory
Virgin Galactic
LVMH
Eni
Medtronic
ProSiebenSat.1
Qualcomm
BioNTech
SIG
Meta (Formerly Facebook)
Philip Morris
Visa
Schlumberger
SMCI
Plug Power
Nike
ADT
3D Systems
Nikola Corporation
Pinterest Inc
Bristol Myers
Jumia Technologies
Broadcom
Upstart Holdings Inc
Salesforce.com
Amazon.com
Cinemark
Moderna Inc
AMC Entertainment Holdings
Air France-KLM
Glencore plc
Starbucks
Uber
Golar LNG
Pfizer
Palantir Technologies Inc
CrowdStrike Holdings
Mastercard
Blackrock
Vir Biotechnology
Toyota
Kuaishou
MerckCo USA
Cisco Systems
Porsche AG
II-VI
Evraz
JD.com
Snap
JP Morgan
Lululemon
UPS
AIA
Deutsche Bank
Airbus Group SE
Zoom Video Communications
XPeng Inc
Trade Desk
AbbVie
Sartorius AG
Mondelez
Hammerson
CNOOC
Snowflake
Thermo Fisher
CCB (Asia)
Kraft Heinz
Unilever
China Life
eBay
Linde PLC
GameStop
Infinera
UnitedHealth
ASOS
SAP
Barclays
Christian Dior
Wish.com Inc
AstraZeneca
FirstRand
SONY
CAT
Applied Materials
BlackBerry
ALIBABA HK
British American Tobacco
AT&T
Siemens
Diageo
Palo Alto Networks
Vipshop
Amgen
Prosus N.V.
ASML
Airbnb Inc
Lithium Americas Corp
JnJ
Wal-Mart Stores
Nasdaq
Exxon Mobil
McDonald's
Shopify
Hermes
Iberdrola
Peloton Interactive Inc.
Ozon
Apple
Volkswagen
Marriott
Sea
Micron
Conoco Phillips
Morgan Stanley
Ford
Upwork Inc.
Nel ASA
Bank of America
Accenture
Santander
Abbott
Trump Media & Technology Group
Royal Bank Canada
UiPath Inc
Spotify
Fedex
LUCID
Anglo American
Allianz
Dave & Buster's
Shell plc (LSE)
Xiaomi
Adidas
Skillz Inc
HDFC Bank
Cellnex
Freeport McMoRan
Wells Fargo
PepsiCo
Berkshire Hathaway
Lockheed Martin
Coinbase Inc
HSBC
Target
Netflix
Vonovia
PayPal
DISNEY
Invesco Mortgage
Blackstone
Boeing Co
Lumentum Holdings
Canopy Growth
Beyond Meat
Block
Qorvo
Delivery Hero SE
Teladoc
Unity Software
PG&E
Microsoft
Gilead
Li Auto
Chevron
Naspers
BP
MercadoLibre.com
Alibaba
New Oriental
CarMax
Lemonade
Citigroup
Two Harbors Investment aration
Taiwan Semi
Total
Bayer
Marston's
Twilio
Home Depot
Oracle
Gen Digital Inc
Baidu
ZIM Integrated Shipping Services Ltd
T-Mobile
Norwegian Cruise Line
ON Semiconductor
American Express
Macy's
Vodafone
L'Oreal
Tesla
Robinhood
Nio
Lloyds
Aptiv PLC
Novavax
Norwegian Air Shuttle
American Airlines
TUI
Annaly Capital
RTX Corp
NVIDIA
Adobe
General Motors
PETROCHINA
Aurora Cannabis Inc
Barrick Gold
Fuelcell
General Electric
Anheuser-Busch Inbev
Continental
Eli Lilly
F5 Networks
Etsy
Hubspot
easyJet
Telecom Italia
Ceconomy
Rio Tinto
AMD
Cameco
Arista
Tencent
British American Tobacco
DeltaAir
Verizon
Airbus
Lufthansa
Teleperformance
GSX Techedu
Rivian Automotive
Wayfair
IBM
Bilibili Inc
HSBC HK
Occidental
Lyft
IAG
Costco
Tilray
Fresnillo
Intel
ROBLOX Corp
BASF
Workday Inc
GoPro
DoorDash
Electrolux
GoHealth
Alphabet (Google)
Tipi di account
Direzione
Quantità
L'ammontare deve essere uguale o superiore a
L’importo deve essere più bassa di
L’importo deve essere un multiplo dell'incremento minimo per i lotti
I risultati del passato non sono un indicatore affidabile dei rendimenti futuri.
Tutte le posizioni sugli strumenti denominati in una valuta diversa dalla valuta del tuo conto saranno soggetti ad una commissione di cambio valuta anche in fase di chiusura della posizione.
Seagen acquisition: Pfizer to acquire cancer drugmaker for $43 billion
Pfizer's $43 billion deal to acquire Seagen, expected to close on Thursday, is projected to add $3.1 billion to revenue next year. The company intends to establish an oncology division in early 2024, led by Chris Boshoff, the current head of cancer research and development for Pfizer.
The U.S. drugmaker anticipates its annual revenue to fall within the range of $58.5 billion to $61.5 billion, compared to analysts' average estimate of $63.17 billion, according to LSEG data.
Pfizer also forecasts an adjusted profit in the range of $2.05 to $2.25 per share — lower than analysts' expectations of $3.16.
Pfizer share price forecast: Most analysts still bullish on PFE stock
Pfizer shares had a consensus Moderate Buy rating as of December 13, according to 14 analysts surveyed by TipRanks offering 12-month price targets on PFE stock. The average price target was $39.73 (a potential 52.75% upside from the stock’s current price), with a high forecast of $75.00 and a low forecast of $25.99.
Goldman Sachs analyst Chris Shibutani remained upbeat about PFE’s prospects, reaffirming a Buy rating on the stock on December 12.
Shibutani believes that the successful conclusion of the “Seagen transaction is an important milestone for Pfizer and meaningfully improves PFE’s end-of-decade revenue outlook.” The analyst also stressed that Seagen’s offerings are backed by compelling clinical data, fueling optimism about Pfizer’s prospects after the deal closes.
At the time of writing on Wednesday, Pfizer shares were trading at $26.01, down over 9% on the day. The pharma giant’s stock has taken a hit this year and is down over 49% year-to-date. PFE’s trajectory has run in stark contrast to the U.S. stock market, with the benchmark S&P 500 index gaining over 21% this year so far.
When considering shares for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.
Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice.
IT
